Tests to Market
We partner with biotech companies to get tests for HIV and STBBIs into the hands of Canadians.
Our work bridges scientific discovery and real-world impact. We conduct rigorous clinical trials required by Health Canada to bring innovative, accurate, and accessible tests for HIV, syphilis, and other STBBIs to market. Our goal is to ensure these life-saving tools reach the people across Canada who need them most.
In 2020, we led the groundbreaking clinical trials that secured approval for Canada’s first HIV self-test.
This landmark breakthrough transformed how people can learn their status, offering privacy, autonomy, and dignity to those often excluded from traditional healthcare settings. Building on that momentum, we have advanced pivotal studies validating a new generation of rapid, point-of-care technologies. In 2023 and 2024, our efforts contributed to the licensing of two dual HIV/syphilis rapid tests and one for syphilis, with several more awaiting imminent approval. Together, these milestones represent a new era of faster and more equitable rapid testing options across the country.
These advancements are only possible by building relationships and partnerships and through deep collaboration.
By working with manufacturers, clinical researchers, community partners, and people with lived experience we ensure every trial we conduct balances scientific rigor with the urgency of expanding timely access to life-saving diagnostics. Our studies range from small pilot projects to large-scale Phase I–III trials, each generating the robust evidence required on safety, performance, and real-world usability.
Our commitment extends to post-market surveillance.
Ensuring that tests continue to meet the highest standards, adapt to emerging needs, respond to evolving public health challenges by testing and connecting people to the care and treatment they need. Through this work, REACH Nexus is driving progress toward a future where testing is faster, more accessible, and truly equitable—bringing us closer to ending the HIV epidemic and reducing the burden of STBBIs in Canada.
